US SB1681 | 2017-2018 | 115th Congress
Status
Spectrum: Partisan Bill (Independent 1-0)
Status: Introduced on July 31 2017 - 25% progression, died in committee
Action: 2017-07-31 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 31 2017 - 25% progression, died in committee
Action: 2017-07-31 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
Title
A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
Sponsors
| Sen. Bernard Sanders [I-VT] |
History
| Date | Chamber | Action |
|---|---|---|
| 2017-07-31 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB3536 (Same As) 2017-08-04 - Referred to the Subcommittee on Health.
Subjects
Drug safety, medical device, and laboratory regulation
Health
Health programs administration and funding
Health technology, devices, supplies
Inflation and prices
Intellectual property
Medical research
Research and development
Health
Health programs administration and funding
Health technology, devices, supplies
Inflation and prices
Intellectual property
Medical research
Research and development
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/115th-congress/senate-bill/1681/all-info |
| Text | https://www.congress.gov/115/bills/s1681/BILLS-115s1681is.pdf |
